Boule Diagnostics AB (ST:BOUL) — Market Cap & Net Worth
Market Cap & Net Worth: Boule Diagnostics AB (BOUL)
Boule Diagnostics AB (ST:BOUL) has a market capitalization of $10.41 Million (Skr96.69 Million) as of September 19, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #27059 globally and #585 in its home market, demonstrating a -11.07% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Boule Diagnostics AB's stock price Skr2.49 by its total outstanding shares 38833104 (38.83 Million). Also see Boule Diagnostics AB balance sheet assets for a full breakdown of the balance sheet.
Boule Diagnostics AB Market Cap History: 2015 to 2026
Boule Diagnostics AB's market capitalization history from 2015 to 2026. Data shows change from $64.30 Million to $10.41 Million (-13.59% CAGR). Also see Boule Diagnostics AB (BOUL) cash flow conversion for how efficiently the company converts equity into cash flow.
Boule Diagnostics AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Boule Diagnostics AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check BOUL stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.07x
Boule Diagnostics AB's market cap is 0.07 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $64.30 Million | $331.41 Million | $15.35 Million | 0.19x | 4.19x |
| 2016 | $198.32 Million | $400.74 Million | $36.03 Million | 0.49x | 5.50x |
| 2017 | $186.11 Million | $427.79 Million | $37.24 Million | 0.44x | 5.00x |
| 2018 | $149.57 Million | $424.40 Million | $41.03 Million | 0.35x | 3.65x |
| 2019 | $197.10 Million | $498.92 Million | $37.55 Million | 0.40x | 5.25x |
| 2020 | $171.95 Million | $400.46 Million | -$47.97 Million | 0.43x | N/A |
| 2021 | $142.29 Million | $463.34 Million | $23.27 Million | 0.31x | 6.11x |
| 2022 | $63.10 Million | $548.09 Million | $12.73 Million | 0.12x | 4.96x |
| 2023 | $46.89 Million | $571.33 Million | $24.98 Million | 0.08x | 1.88x |
| 2024 | $37.53 Million | $558.60 Million | -$223.30 Million | 0.07x | N/A |
Competitor Companies of BOUL by Market Capitalization
Companies near Boule Diagnostics AB in the global market cap rankings as of September 19, 2026. Review Boule Diagnostics AB (BOUL) tangible net worth to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Boule Diagnostics AB by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #124 globally with a market cap of $178.43 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #228 globally with a market cap of $109.30 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #238 globally with a market cap of $105.53 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #240 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #124 | Abbott Laboratories | NYSE:ABT | $178.43 Billion | $102.61 |
| #228 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $92.13 |
| #238 | Stryker Corporation | NYSE:SYK | $105.53 Billion | $275.12 |
| #240 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Boule Diagnostics AB Historical Marketcap From 2015 to 2026
Between 2015 and today, Boule Diagnostics AB's market cap moved from $64.30 Million to $ 10.41 Million, with a yearly change of -13.59%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr10.41 Million | -49.29% |
| 2025 | Skr20.52 Million | -45.32% |
| 2024 | Skr37.53 Million | -19.96% |
| 2023 | Skr46.89 Million | -25.70% |
| 2022 | Skr63.10 Million | -55.65% |
| 2021 | Skr142.29 Million | -17.25% |
| 2020 | Skr171.95 Million | -12.76% |
| 2019 | Skr197.10 Million | +31.78% |
| 2018 | Skr149.57 Million | -19.63% |
| 2017 | Skr186.11 Million | -6.16% |
| 2016 | Skr198.32 Million | +208.41% |
| 2015 | Skr64.30 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Boule Diagnostics AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $10.41 Million USD |
| MoneyControl | $10.41 Million USD |
| MarketWatch | $10.41 Million USD |
| marketcap.company | $10.41 Million USD |
| Reuters | $10.41 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Boule Diagnostics AB
Boule Diagnostics AB (publ) develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and the Middle East. The company provides hematology analyzers, reagents, controls, and calibrators, under the Swelab, Medonic, and Quintus brands; and veterinary hematology and clini… Read more